<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370869">
  <stage>Registered</stage>
  <submitdate>8/06/2016</submitdate>
  <approvaldate>1/07/2016</approvaldate>
  <actrnumber>ACTRN12616000863437</actrnumber>
  <trial_identification>
    <studytitle>Functional MRI assessment of primary and secondary brain tumour response to radiation therapy: A pilot study</studytitle>
    <scientifictitle>Functional MRI assessment of primary and secondary brain tumour response to radiation therapy: A pilot study</scientifictitle>
    <utrn />
    <trialacronym>Serial CNS MRI Study</trialacronym>
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Brain Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Brain</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study involves observing radiotherapy treatment response using novel MRI sequences as imaging biomarkers in participants undergoing standard radiotherapy and/or chemotherapy treatment.
Standard Treatment - DW, DCE, SWI and ASL MRI at radiotherapy simulation (Radiotherapy treatment planning to map out treatment delivery) (week 0)
Radiotherapy begins at Week 1
Extra test for pts on study
- DW, DCE, SWI and ASL MRI (weeks 3 and 6) 
- at 4 weeks post RT - DW, DCE, SWI and ASL MRI
Abbreviations: DW = diffusion weighted; DCE = dynamic contrast enhanced; SWI = susceptibility weighted imaging; ASL = Arterial spin labelling
These scan are to gain anatomical and physiological information.
The MRI images will require administration of an intravenous contrast agent. The MRI scan will take approximately 30-45 minutes and a contrast agent will be administered through a cannula during this examination. The MRIs will be undertaken by clinical MRI and radiotherapy staff with expertise required for clinical use of this imaging modality</interventions>
    <comparator>MRI are compared from Week 0 to
- DW, DCE, SWI and ASL MRI (weeks 3 and 6) 
- at 4 weeks post RT - DW, DCE, SWI and ASL MRI
</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine early treatment response and/or disease progression post cancer therapy using novel MRI sequences (including DW and DCE-MRI) in CNS cancer patients.</outcome>
      <timepoint>Baseline, Week 3, Week 6 and 4 Weeks post Radiotherapy

Baseline - DW, DCE, SWI and ASL MRI at radiotherapy simulation (week 0)
Weeks 3 and 6 - DW, DCE, SWI and ASL MRI 
4 Weeks post RT - DW, DCE, SWI and ASL MRI
Abbreviations: DW = diffusion weighted; DCE = dynamic contrast enhanced; SWI = susceptibility weighted imaging; ASL = Arterial spin labelling</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To document serial hippocampal volumetric changes post cancer therapy using novel MRI sequences.</outcome>
      <timepoint>Baseline, Week 3, Week 6 and 4 Weeks post Radiotherapy

Baseline - DW, DCE, SWI and ASL MRI at radiotherapy simulation (week 0)
Weeks 3 and 6 - DW, DCE, SWI and ASL MRI 
4 Weeks post RT - DW, DCE, SWI and ASL MRI
Abbreviations: DW = diffusion weighted; DCE = dynamic contrast enhanced; SWI = susceptibility weighted imaging; ASL = Arterial spin labelling</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>18 years or older
Have the ability to give informed consent
Histologically-proven primary or secondary brain cancer 
Plan to have radiotherapy treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindication to MRI studies
Significant claustrophobia
Pacemaker/implantable defibrillator
Implanted metals eg. Intraocular clips
Known allergic reaction to Gd-DTPA
Previous CNS radiotherapy 
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>14/07/2016</anticipatedstartdate>
    <actualstartdate>23/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Eng-Siew Koh</primarysponsorname>
    <primarysponsoraddress>Liverpool Hospital
Elizabeth St &amp; Goulburn St, Liverpool NSW 2170</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Liverpool Hospital</fundingname>
      <fundingaddress>Elizabeth St &amp; Goulburn St, Liverpool NSW 2170</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This pilot study will determine the relationship between of pre-, during treatment and post-radiotherapy (+/- chemotherapy) MRI sequences (including DW and DCE-MRI) with respect to CNS tumour response and local intra-cranial control, post radiotherapy.
and also determine the utility of MRI for assessing changes to the hippocampal region from CNS radiation therapy 

Who is it for?
You may be eligible to join this study if you are aged 18 years or above, have been newly diagnosed with primary or secondary brain cancer.

Study details
Participants will undergo normal MRI testing at baseline with an addition of 3 more times.
During RT (Week 3 and 6) and then again 4 weeks post RT</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Western Sydney Local Health District</ethicname>
      <ethicaddress>Elizabeth St &amp; Goulburn St, Liverpool NSW 2170</ethicaddress>
      <ethicapprovaldate>13/06/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>27/05/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Eng-Siew Koh</name>
      <address>Liverpool Hospital
Locked Bag 7103, Liverpool BC, NSW 1871</address>
      <phone>+61 2 8738 9806 </phone>
      <fax>+61 2 8738 9819 </fax>
      <email>eng-siew.koh@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Samantha Gillman</name>
      <address>Liverpool Hospital
Locked Bag 7103, Liverpool BC, NSW 1871 </address>
      <phone>+61 2 8738 9146 </phone>
      <fax>+61 2 8738 9205 </fax>
      <email>samantha.gillman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Jameson</name>
      <address>1 Campbell St, Liverpool NSW 2170</address>
      <phone>+61 2 8738 9219 </phone>
      <fax />
      <email>michael.jameson@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Samantha Gillman</name>
      <address>Liverpool Hospital
Locked Bag 7103, Liverpool BC, NSW 1871 </address>
      <phone>+61 2 8738 9146 </phone>
      <fax>+61 2 8738 9205 </fax>
      <email>samantha.gillman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>